Sun Pharmaceutical Industries (SUNPHARMA.BO) Earnings Analysis

Sun Pharmaceutical Industries (SUNPHARMA.BO) next reports earnings on 2026-07-31, consensus EPS 12.53 INR. Last quarter (2026-05-22) it missed with EPS 11.3 INR vs 11.34 INR est (-0.4%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E 40.80.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SUNPHARMA.BO next report earnings?

Next earnings date2026-07-31
Consensus EPS estimate12.53 INR
Revenue estimate154.74B

SUNPHARMA.BO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-2211.3 INR11.34 INR-0.4%Miss
2026-01-3114.7 INR12.91 INR+13.9%Beat
2025-07-3112 INR12.52 INR-4.2%Miss
2025-05-2210.8 INR11.65 INR-7.3%Miss
2025-01-3113.4 INR11.98 INR+11.9%Beat
2024-10-2812.7 INR11.62 INR+9.3%Beat
2024-08-0111.8 INR10.51 INR+12.3%Beat

Beat rate: 4/7 (57%) over reported quarters with consensus data.

SUNPHARMA.BO valuation and analyst view

Trailing P/E40.80
Trailing EPS47.795 INR
Price / book5.61
Dividend yield0.82%
Market cap4661.19B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Sun Pharmaceutical Industries (SUNPHARMA.BO)'s next earnings date?

Sun Pharmaceutical Industries is next scheduled to report on 2026-07-31, with a consensus EPS estimate of 12.53 INR and revenue estimate of 154.74B.

Did SUNPHARMA.BO beat earnings last quarter?

In its 2026-05-22 report, SUNPHARMA.BO posted EPS of 11.3 INR versus a 11.34 INR estimate — a miss of 0.4%.

What is SUNPHARMA.BO's earnings track record?

Over the last 7 reported quarters with consensus data, SUNPHARMA.BO beat estimates 4 times (57%).

What is SUNPHARMA.BO's current P/E ratio and EPS?

SUNPHARMA.BO trades at a trailing P/E of 40.80 on trailing EPS of 47.795149962777856 INR.

What do analysts rate SUNPHARMA.BO?

SUNPHARMA.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.